| Name | Title | Contact Details |
|---|
Cyagen Biosciences is a 400-employee company headquartered in Santa Clara, California, with additional locations in Germany, Japan and China. Cyagen is the world`s largest provider of custom-engineered mouse and rat models. Cyagen`s services have become well known for their top quality, full guarantee, and competitive prices.
Verax Biomedical Incorporated is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Singlera Genomics Inc., a fast growing company focusing on non-invasive genetic testing, was co-founded in July 2014 in San Diego, California by Professor Yuan Gao (Johns Hopkins University), Professor Kun Zhang (University of California at San Diego), Mr. Jiangli Zhang (CEO), Mr. Qiang Liu (COO), and Dr. Rui Liu (CTO). The company currently has an R&D center in La Jolla, California, and a business and clinical operation site in Shanghai, China. Singlera has proprietary technologies in single cell sequencing, DNA methylation and bioinformatics. In the past decade, Professor Gao, Professor Zhang and Dr. Liu have made outstanding achievements in their respective scientific research fields, and have published hundreds of research papers in top level scientific journals. These publications include 20+ papers in Cell, Nature, and Science. In recent years Professor Gao, Professor Zhang, and Dr. Liu have expanded their efforts to translational diagnostics, and have applied their expertise to develop genetic tests. Singlera is committed to the application of Next Generation Sequencing technologies, to diagnose genetic diseases and disorders. Singlera`s main products and services include tumor diagnosis and personalized treatment, non-invasive prenatal diagnosis, pre-implantation genetic screening, and customized scientific research services. Singlera is dedicated to the development of precision medicine, striving to help the patients through early, accurate and informative diagnoses.
ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that dramatically enhance the therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.
Aspect DV is a Merrimack, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.